Peer Exchange

The Pharmacy Times® Peer Exchange series is built around video panel discussions featuring some of the most recognizable names in pharmaceuticals. Each program focuses on a specific disease, condition, or therapy, and boasts energetic, moderated conversation on a variety of subjects and questions pertaining to the topic at hand.

What can we help you find?
How biologics have changed clinical practice over conventional chemotherapies and currently available biosimilars in the US.
A review of the impact of biosimilars on cancer treatment.
A discussion on the adoption of biosimilars in the US vs Europe and the potential cost savings associated.
The panel explores the extrapolation of indications of biosimilars compared with the original product.
Defining what it means to have an “interchangeability” designation as it relates to biosimilars and insight on challenges with regulations of holding this status.
A review of the steps of the FDA approval process for biosimilars and a discussion on immunogenicity and quality assurance for biosimilars.
Clinical pharmacists provide an overview of the similarities and differences of biosimilars vs biologics including a comparison of dosing and storage conditions.
Future of Management
A consideration of whether the AVANOVA phase 2 mono- or combination therapy is preferable, and a discussion on the future of ovarian cancer management.
HSE, ovarian cancer, oncology
Expert oncologists and pharmacists discuss the significance of chemotherapy-free regimens in later-line settings, and the role of specialty pharmacists to direct individuals toward the appropriate treatment plan.
A discussion on when to optimally use PARP inhibitors in patients with platinum-sensitive recurrent disease and the potential for PARPi re-treatment.
Key opinion leaders consider whether frontline bevacizumab will affect second-line therapy options.
Platinum-Sensitive vs Platinum-Resistant Recurrence
Maurie Markman, MD, leads a discussion on defining platinum-sensitive versus platinum-resistant recurrent disease, and the role of immunotherapy in managing ovarian cancer.